- Researchers investigated whether gene expression patterns in immature blood-forming cells could improve survival predictions for patients with myelofibrosis.
- The study analyzed 358 blood samples using RNA sequencing, a method of measuring gene activity, to develop a 24-gene score.
- High-risk scores correlated with a 25.5 percent 5-year survival versus 86.9 percent for low-risk scores (HR 9.81, P=4.0e-11).
- This score maintained independent prognostic significance when added to existing clinical models, such as the Dynamic International Prognostic Scoring System.
- This tool specifically improves risk stratification for patients currently categorized as intermediate or high risk by standard clinical criteria.
Refining Prognostic Precision in Myelofibrosis
Myelofibrosis remains a clinically heterogeneous myeloid neoplasm where the timing of definitive intervention is often obscured by variable disease trajectories. While Janus kinase inhibitors effectively manage splenomegaly and constitutional symptoms, they rarely induce molecular remissions or fundamentally alter the natural history of the disease [1, 2, 3]. Allogeneic hematopoietic stem cell transplantation offers the only potential for a cure, yet it carries substantial risks of treatment-related mortality and chronic graft-versus-host disease [4, 5]. Current management relies on clinical scoring systems and mutation-enhanced models to guide these high-stakes decisions, but these tools often fall short in predicting outcomes for patients with intermediate-risk phenotypes [6, 7]. To address this diagnostic gap, researchers recently investigated whether analyzing the gene expression patterns of the underlying stem cell population could provide a more precise prognostic tool for complex clinical scenarios.
Developing the MPN24 Transcriptomic Signature
The researchers hypothesized that analyzing transcriptomic features (the complete set of RNA transcripts reflecting real-time gene activity) within disease-driving hematopoietic stem and progenitor cells could refine current risk stratification for myelofibrosis. To test this, they performed bulk RNA sequencing, a method that measures average gene expression across a large cell population, using blood samples from 358 patients with myelofibrosis divided into training and test cohorts. To ensure the model captured the specific biology of the malignant clone, the researchers utilized single-cell RNA sequencing data from Lin-CD34+ hematopoietic stem and progenitor cells (immature blood-forming cells that lack mature lineage markers but express the CD34 protein). This high-resolution cellular data guided the development of a prognostic model trained on the larger bulk RNA sequencing dataset. From this analysis, the researchers identified a 24-gene weighted-sum expression score, designated as MPN24, which proved to be a significant predictor of overall survival. The team then transitioned this signature to a NanoString assay, a clinical platform that quantifies gene expression directly without the need for complex sequencing libraries, to validate the model in two independent cohorts. By identifying high-risk transcriptomic profiles that standard clinical and mutation-based tools may overlook, the MPN24 score provides a more granular assessment of patient prognosis, raising the prospect of matching patients to targeted interventions based on their specific molecular profile.
Survival Divergence in Independent Validation Cohorts
The researchers validated the MPN24 score in an independent cohort of 170 patients with myelofibrosis, where the transcriptomic signature revealed a stark divergence in clinical outcomes. Patients classified as MPN24-high had a 5-year overall survival of 25.5%, while those in the MPN24-low group demonstrated a 5-year overall survival of 86.9%. This substantial gap in survival highlights the capacity of the score to distinguish between patients with vastly different disease trajectories. The statistical magnitude of this risk was evidenced by a hazard ratio for overall survival of 9.81 (P = 4.0e-11) in this 170-patient cohort. These findings were further confirmed in a second independent cohort of 100 patients, reinforcing the reliability of the gene expression score across different clinical settings. Within this group, MPN24-high scoring patients had a 5-year overall survival of 23.5%, which stood in sharp contrast to the 75.9% 5-year overall survival observed in MPN24-low scoring patients. The hazard ratio for overall survival in this 100-patient cohort was 6.40 (P = 1.8e-7). For the practicing clinician, these results suggest that the MPN24 score can reliably identify high-risk individuals who may require more intensive monitoring or earlier consideration for aggressive therapeutic interventions, such as allogeneic stem cell transplantation.
Integration with Established Risk Models
The researchers observed that high MPN24 scores were associated with clinical, mutation, and karyotypic features (abnormal chromosomal arrangements) that are already recognized as indicators of adverse risk in myelofibrosis. This correlation suggests that the transcriptomic signature accurately reflects the underlying biological complexity of the disease. However, the score is not merely a surrogate for these established markers. In a multivariable analysis (a statistical method used to determine the independent effect of a variable while adjusting for other factors), the MPN24 score retained independent prognostic significance. This indicates that the 24-gene signature captures unique biological information regarding patient survival that is not fully accounted for by standard clinical or genomic covariates. The clinical utility of the MPN24 score is further demonstrated by its ability to refine existing risk stratification tools. When integrated into current models, the score added significant prognostic value to the Dynamic International Prognostic Scoring System (DIPSS) with a P-value of 1.6e-5 and to the DIPSS plus system with a P-value of 4.0e-6. The researchers also evaluated the score against more modern, mutation-based frameworks. The MPN24 score provided significant prognostic value to the Mutation-Enhanced International Prognostic Score System (MIPSS70) with a P-value of 1.5e-6 and to the MIPSS70 plus version 2.0 with a P-value of 5.4e-4. These results suggest that the transcriptomic signature can enhance the precision of survival estimates across the spectrum of currently utilized clinical and molecular scoring systems, helping physicians better weigh the risks and benefits of transplant versus medical management.
Clinical Utility for Intermediate-Risk Patients
The clinical management of myelofibrosis often hinges on the distinction between patients who can be safely monitored and those who require immediate, aggressive intervention. This decision is particularly challenging for patients categorized into middle-tier risk groups, where survival outcomes are highly variable. The researchers found that the MPN24 score was particularly useful in improving risk-stratification of DIPSS-intermediate patients, a group that frequently presents a therapeutic dilemma in clinical practice. By identifying individuals within this intermediate category who possess a high-risk transcriptomic profile, the score allows clinicians to recognize patients who may have a more aggressive disease course than their baseline clinical features suggest. Beyond clinical scoring systems, the transcriptomic signature also adds precision to models that already incorporate molecular data. The study demonstrated that the MPN24 score improved risk-stratification for MIPSS70-intermediate and high-risk patients, providing a more granular view of survival probability even when mutational status is known. This refinement is driven by the origin of the score in disease-driving hematopoietic stem and progenitor cells, the immature cells in the bone marrow responsible for the progression of the neoplasm. By capturing the underlying biological activity of these specific cells, the MPN24 score refines the current stratification paradigm and assists physicians in identifying high-risk patients who might otherwise be misclassified by standard clinical and mutation-based frameworks.
References
1. Verstovšek S, Mesa RA, Gotlib J, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine. 2012. doi:10.1056/nejmoa1110557
2. investigators FTC, Verstovšek S, Mesa RA, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology & Oncology. 2017. doi:10.1186/s13045-017-0417-z
3. Ross DM, Lane SW, Harrison CN. Identifying disease-modifying potential in myelofibrosis clinical trials.. Blood. 2024. doi:10.1182/blood.2024024220
4. Bewersdorf JP, Sheth AH, Vetsa S, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.. Transplantation and cellular therapy. 2021. doi:10.1016/j.jtct.2021.05.016
5. Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials. Journal of Clinical Oncology. 2005. doi:10.1200/jco.2005.09.020
6. Chen K, Zhang Y, Zou J, et al. Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis.. Frontiers in oncology. 2024. doi:10.3389/fonc.2024.1403967
7. Gupta V, Harrison C, Gorsh B, et al. Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials. Blood. 2023. doi:10.1182/blood-2023-178772